These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25690588)

  • 41. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.
    Barter P; Ginsberg HN
    Am J Cardiol; 2008 Oct; 102(8):1040-5. PubMed ID: 18929706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment options for managing atherogenic dyslipidemia and fatty liver disease.
    Rizzo M; Montalto G; Al-Rasadi K
    Expert Opin Pharmacother; 2014 Jun; 15(8):1065-8. PubMed ID: 24673432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Consensus statement on the management of dyslipidaemias in adults.
    ; ; ; Béliard S; Bonnet F; Bouhanick B; Bruckert E; Cariou B; Charrière S; Durlach V; Moulin P; Valéro R; Vergès B
    Diabetes Metab; 2016 Dec; 42(6):398-408. PubMed ID: 27659248
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
    Nichols GA; Reynolds K; Olufade T; Kimes TM; O'Keeffe-Rosetti M; Sapp DS; Anzalone D; Fortmann SP
    Am J Cardiol; 2017 Feb; 119(3):410-415. PubMed ID: 27890243
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS
    Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dyslipidemias in chronic kidney disease.
    Szromba C
    Nephrol Nurs J; 2006; 33(5):575-6. PubMed ID: 17044444
    [No Abstract]   [Full Text] [Related]  

  • 48. Dyslipidemia in the elderly: should it be treated?
    Shanmugasundaram M; Rough SJ; Alpert JS
    Clin Cardiol; 2010 Jan; 33(1):4-9. PubMed ID: 20063295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Do persons with stroke benefit from statin-fibrate combination therapy?
    Castilla-Guerra L; Fernandez-Moreno Mdel C
    Eur J Intern Med; 2015 Mar; 26(2):148-9. PubMed ID: 25620642
    [No Abstract]   [Full Text] [Related]  

  • 50. Dyslipidemia: management using optimal lipid-lowering therapy.
    Ito MK
    Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Critical review of non-statin treatments for dyslipoproteinemia.
    Pang J; Chan DC; Watts GF
    Expert Rev Cardiovasc Ther; 2014 Mar; 12(3):359-71. PubMed ID: 24506448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low.
    Athyros VG; Wierzbicki AS
    Curr Med Res Opin; 2014 Jan; 30(1):57-8. PubMed ID: 24160920
    [No Abstract]   [Full Text] [Related]  

  • 53. Treating antiretroviral-induced dyslipidemia in HIV-infected adults.
    Scordo KA
    Nurse Pract; 2010 Jul; 35(7):32-7; quiz 37-8. PubMed ID: 20555242
    [No Abstract]   [Full Text] [Related]  

  • 54. [Clinical evidence of statins and fibrates in the management of dyslipidemia in Japan].
    Hara M; Kinoshita M
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():621-5. PubMed ID: 21766671
    [No Abstract]   [Full Text] [Related]  

  • 55. Combination therapy in dyslipidemia: where are we now?
    Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidelines related to the diagnostics and treatment of dyslipidemias issued in 2011].
    Soška V; Vaverková H; Vráblík M; Bláha V; Cífková R; Freiberger T; Kraml P; Piťha J; Rosolová H; Stulc T; Urbanová Z
    Vnitr Lek; 2013 Feb; 59(2):120-6. PubMed ID: 23461401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Lipid therapy in daily routine].
    Sonntag F; Schaefer JR; Gitt AK; Weizel A; Jannowitz C; Karmann B; Pittrow D; Bestehorn K
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2047-52. PubMed ID: 23023622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes.
    Durrington PN
    Evid Based Med; 2015 Feb; 20(1):12. PubMed ID: 25249694
    [No Abstract]   [Full Text] [Related]  

  • 60. Forecasting cholesterol management--end of the statin gold rush?
    Crownover BK; Curtiss FR
    J Manag Care Pharm; 2006; 12(6):479-85. PubMed ID: 16925456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.